ライフサイエンスコーパス: intrahepatic cholangiocarcinoma

1 , increased cholangiocyte proliferation, and intrahepatic cholangiocarcinoma.

2 ed for radioembolization in locally advanced intrahepatic cholangiocarcinoma.

3 with the highest incidences among those with intrahepatic cholangiocarcinoma.

4 up to 25% of cholangiocarcinomas, especially intrahepatic cholangiocarcinoma.

5 % were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma.

6 llular carcinoma with stem cell features and intrahepatic cholangiocarcinoma.

7 a target of transformation and an origin of intrahepatic cholangiocarcinoma.

8 epatocytes in this model as well as in human intrahepatic cholangiocarcinoma.

9 itumor effects in an orthotopic rat model of intrahepatic cholangiocarcinoma.

10 ncreasing in frequency as is that of primary intrahepatic cholangiocarcinoma.

11 ors, several others could be associated with intrahepatic cholangiocarcinoma.

12 ce, mortality, and survival rates of primary intrahepatic cholangiocarcinoma.

13 served in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinomas.

14 soforms 1 or 2 occur in approximately 15% of intrahepatic cholangiocarcinomas.

15 ehydrogenase (IDH) is recurrently mutated in intrahepatic cholangiocarcinomas.

16 tly expanded the genetic characterization of intrahepatic cholangiocarcinomas.

17 and IDH2 genes encoding metabolic enzymes in intrahepatic cholangiocarcinomas.

18 role of dysregulated chromatin remodeling in intrahepatic cholangiocarcinomas.

19 osis and most of the tumors that formed were intrahepatic cholangiocarcinomas.

20 ), non-colorectal liver metastases (7%), and intrahepatic cholangiocarcinoma (6%).

21 occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon c

22 We identified all patients with intrahepatic cholangiocarcinoma aged 65 years and older

23 broblast growth factor receptor-2 fusions in intrahepatic cholangiocarcinoma, among others) is changi

24 Results: In total, 10 patients (6 with intrahepatic cholangiocarcinoma and 4 with extrahepatic

25 ate the prevalence of known risk factors for intrahepatic cholangiocarcinoma and explore other potent

26 f patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets

27 contrast enhancement is a typical feature of intrahepatic cholangiocarcinoma and may aid in the detec

28 tic reviews of all series on TO indications (intrahepatic cholangiocarcinoma and perihilar cholangioc

29 103 patients obtained from meta-analyses on intrahepatic cholangiocarcinoma and phCC, and liver meta

30 ondary glioblastoma, acute myeloid leukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, le

31 s, acute-on-chronic liver failure, hilar and intrahepatic cholangiocarcinoma, and unresectable liver

32 hepatocellular carcinoma, hepatoblastoma and intrahepatic cholangiocarcinoma are analyzed, obtaining

33 cers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are leading causes of c

34 Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis an

35 een increasingly used to treat patients with intrahepatic cholangiocarcinoma, as well as metastatic d

36 cancers including hepatocellular carcinomas, intrahepatic cholangiocarcinomas, basal cell carcinomas,

37 markers made progresses slowly compared with intrahepatic cholangiocarcinoma because of surgical comp

38 constitute a novel therapeutic approach for intrahepatic cholangiocarcinoma, because this protein al

39 Intrahepatic cholangiocarcinoma (CCA) is a lethal malign

40 Intrahepatic cholangiocarcinoma (CCA) is characterized b

41 s of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA).

42 e to enrich for cell surface proteins of the intrahepatic cholangiocarcinoma cell line CC-SW-1 was de

43 s inhibitor celecoxib on the growth of human intrahepatic cholangiocarcinoma cells.

44 equencing of 133 combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC) cases, includ

45 associated with hepatocellular carcinoma and intrahepatic cholangiocarcinoma development.

46 1 activity was high throughout the course of intrahepatic cholangiocarcinomas development and low dur

47 ve consortium of malignancies, consisting of intrahepatic cholangiocarcinoma, extrahepatic cholangioc

48 inactivation of Vgll4 dramatically enhanced intrahepatic cholangiocarcinoma formation in Nf2-deficie

49 t also produced a significant suppression of intrahepatic cholangiocarcinoma growth when administered

50 The incidence of intrahepatic cholangiocarcinoma has been recently increa

51 sociated fibroblastic cells in the stroma of intrahepatic cholangiocarcinoma has recently been demons

52 ly encompassing hepatocellular carcinoma and intrahepatic cholangiocarcinoma, has become the second l

53 primary modality of treatment for hilar and intrahepatic cholangiocarcinoma (HCCA-ICCA).

54 Seven patients had nodules demonstrating intrahepatic cholangiocarcinoma (I-CCA), nine had I-CCA

55 ), bile ducts and liver (CD/UC), liver (CD), intrahepatic cholangiocarcinoma (IBDs), bile ducts (CD),

56 Intrahepatic cholangiocarcinoma (ICC) accounts for 12% o

57 owth Factor Receptor 2 (FGFR2) are common in intrahepatic cholangiocarcinoma (ICC) and confer sensiti

58 ed unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic c

59 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular

60 Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar cholangi

61 s study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin ly

62 on outcomes following surgical management of intrahepatic cholangiocarcinoma (ICC) are limited.

63 at mediate the initiation and development of intrahepatic cholangiocarcinoma (ICC) associated with he

64 Staging of intrahepatic cholangiocarcinoma (ICC) has historically m

65 rom combined hepatocellular liver cancer and intrahepatic cholangiocarcinoma (ICC) has increased and

66 rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in

67 We aimed to examine the burden of intrahepatic cholangiocarcinoma (ICC) in Thailand and id

68 Intrahepatic cholangiocarcinoma (ICC) is a highly aggres

69 Intrahepatic cholangiocarcinoma (ICC) is a highly malign

70 Intrahepatic cholangiocarcinoma (ICC) is a primary cance

71 Intrahepatic cholangiocarcinoma (ICC) is a severe malign

72 PURPOSE OF REVIEW: Intrahepatic cholangiocarcinoma (ICC) is a treatment-ref

73 Intrahepatic cholangiocarcinoma (ICC) is aggressive and

74 Intrahepatic cholangiocarcinoma (ICC) is an aggressive b

75 Intrahepatic cholangiocarcinoma (ICC) is an aggressive m

76 Intrahepatic cholangiocarcinoma (ICC) is asevere maligna

77 rgical tumor resection (R0) for treatment of intrahepatic cholangiocarcinoma (ICC) is potentially cur

78 Intrahepatic cholangiocarcinoma (ICC) is the second most

79 Intrahepatic cholangiocarcinoma (ICC) is the second most

80 Intrahepatic cholangiocarcinoma (ICC) likely originates

81 st common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic ch

82 and 87.5%, 70.0% and 70.0% for patients with intrahepatic cholangiocarcinoma (ICC) respectively.

83 ions between diabetes, smoking, obesity, and intrahepatic cholangiocarcinoma (ICC) risk remain inconc

84 on of overall survival (OS) in patients with Intrahepatic Cholangiocarcinoma (ICC) who underwent conv

85 Our study investigates CAF functions in intrahepatic cholangiocarcinoma (ICC), a highly desmopla

86 232R) of PTPN3, a frequent mutation found in intrahepatic cholangiocarcinoma (ICC), disables its role

87 In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic ben

88 on and aggressive malignancy of mass-forming intrahepatic cholangiocarcinoma (ICC), we modeled ICC de

89 cells treated with wild-type or IDH1 mutant intrahepatic cholangiocarcinoma (ICC)-derived EVs uncove

90 to induce hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).

91 cated a possible association between HCV and intrahepatic cholangiocarcinoma (ICC).

92 including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).

93 Intrahepatic cholangiocarcinoma (iCCA) and hepatocellula

94 Primary liver cancer (PLC), which includes intrahepatic cholangiocarcinoma (iCCA) and hepatocellula

95 Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellula

96 Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly

97 Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of

98 he 3-year overall survival (OS) for advanced intrahepatic cholangiocarcinoma (iCCA) confined to the l

99 Limited treatment options in patients with intrahepatic cholangiocarcinoma (iCCA) demand the introd

100 Intrahepatic cholangiocarcinoma (iCCA) denotes a rare, h

101 Intrahepatic cholangiocarcinoma (iCCA) has over the last

102 Intrahepatic cholangiocarcinoma (iCCA) has previously be

103 Intrahepatic cholangiocarcinoma (iCCA) is a contraindica

104 Intrahepatic cholangiocarcinoma (iCCA) is a contraindica

105 Intrahepatic cholangiocarcinoma (iCCA) is a fatal bile d

106 Intrahepatic cholangiocarcinoma (iCCA) is a lethal malig

107 Intrahepatic cholangiocarcinoma (iCCA) is the second mos

108 Intrahepatic cholangiocarcinoma (iCCA) presents a challe

109 performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumo

110 We report a case of a 55-year-old male with intrahepatic cholangiocarcinoma (iCCA) who underwent liv

111 Intrahepatic cholangiocarcinoma (iCCA) with liver metast

112 activation of YAP/TAZ, rapid development of intrahepatic cholangiocarcinoma (iCCA), and early lethal

113 er comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare t

114 Biliary tract cancers (BTCs), including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cho

115 In advanced, liver-only intrahepatic cholangiocarcinoma (iCCA), selective intern

116 inhibitors (FGFRi) are used for treatment of intrahepatic cholangiocarcinoma (iCCA), understanding po

117 ng rise to hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICCA).

118 es, IDH mutations are particularly common in intrahepatic cholangiocarcinoma (iCCA).

119 four hepatocellular carcinoma, HCC and three intrahepatic cholangiocarcinoma, iCCA).

120 Intrahepatic cholangiocarcinomas (ICCs) are primary live

121 About 15% of intrahepatic cholangiocarcinomas (ICCs) express constitu

122 102 hepatocellular carcinomas (HCCs), three intrahepatic cholangiocarcinomas (ICCs), one neuroendocr

123 Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar chol

124 ata suggesting a rising worldwide incidence, intrahepatic cholangiocarcinoma (IHC) remains an uncommo

125 Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective.

126 Intrahepatic cholangiocarcinoma (IHCC) is a primary canc

127 among the most common genetic alterations in intrahepatic cholangiocarcinoma (IHCC), a deadly liver c

128 increase in the incidence and mortality from intrahepatic cholangiocarcinoma in the United States in

129 termine recent trends in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

130 Intrahepatic cholangiocarcinoma is a treatment refractor

131 The incidence of intrahepatic cholangiocarcinoma is increasing worldwide.

132 in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally.

133 1997, the incidence and mortality rates from intrahepatic cholangiocarcinoma markedly increased, with

134 ver tumors (hepatocellular carcinoma: n = 3, intrahepatic cholangiocarcinoma: n = 2, extrahepatic cho

135 ocellular carcinoma and 1.06 (1.01-1.11) for intrahepatic cholangiocarcinoma (p(heterogeneity)=0.82).

136 ngiocarcinoma cells in relation to promoting intrahepatic cholangiocarcinoma progression is only just

137 alk with cholangiocarcinoma cells to promote intrahepatic cholangiocarcinoma progression.

138 r-associated fibroblastic cells in promoting intrahepatic cholangiocarcinoma progression.

139 ted in an orthotopic, syngeneic rat model of intrahepatic cholangiocarcinoma progression.

140 , despite significant genetic heterogeneity, intrahepatic cholangiocarcinoma relies on a limited numb

141 f cHCC-ICC with hepatocellular carcinoma and intrahepatic cholangiocarcinoma revealed that combined a

142 pment of novel multitargeting strategies for intrahepatic cholangiocarcinoma therapy.

143 Intrahepatic cholangiocarcinoma typically presents in an

144 e vs recurrent) and primary tumour location (intrahepatic cholangiocarcinoma vs extrahepatic cholangi

145 Through exomic sequencing of 32 intrahepatic cholangiocarcinomas, we discovered frequent

146 could classify hepatocellular carcinoma and intrahepatic cholangiocarcinoma with an sensitivity and

147 BDEsp cells yielded only small nonmetastatic intrahepatic cholangiocarcinomas without bile duct obstr